Daewoong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Daewoong Pharmaceutical has a total shareholder equity of ₩912.3B and total debt of ₩437.4B, which brings its debt-to-equity ratio to 47.9%. Its total assets and total liabilities are ₩1,770.3B and ₩858.0B respectively. Daewoong Pharmaceutical's EBIT is ₩121.1B making its interest coverage ratio 11.5. It has cash and short-term investments of ₩137.7B.
Key information
47.9%
Debt to equity ratio
₩437.37b
Debt
Interest coverage ratio | 11.5x |
Cash | ₩137.68b |
Equity | ₩912.28b |
Total liabilities | ₩858.03b |
Total assets | ₩1.77t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A069620's short term assets (₩574.8B) do not cover its short term liabilities (₩667.1B).
Long Term Liabilities: A069620's short term assets (₩574.8B) exceed its long term liabilities (₩190.9B).
Debt to Equity History and Analysis
Debt Level: A069620's net debt to equity ratio (32.8%) is considered satisfactory.
Reducing Debt: A069620's debt to equity ratio has reduced from 63.6% to 47.9% over the past 5 years.
Debt Coverage: A069620's debt is well covered by operating cash flow (31.1%).
Interest Coverage: A069620's interest payments on its debt are well covered by EBIT (11.5x coverage).